University of Southern California
USC Norris Comprehensive Cancer Center
If you are a patient, please contact Keck Medical Center of USC at 800-USC-CARE.

Optical Imaging: Xenogen IVIS 200




Comparatively inexpensive technique for noninvasive study of molecular targets inside the body of the living animals. Optical imaging utilizes a variety of labeled molecules: bioluminescence, fluorescent proteins, and fluorescent dyes or nanoparticles. Research applications include in vivo tracking and monitoring of tumor cells, bacteria, stem cells, and also the study of gene function.

Xenogen IVIS 200 Imaging Series: This system allows researchers to use real-time, noninvasive imaging to monitor and record cellular and genetic activity in vivo. Integrated into the system are both a bioluminescence system and a fluorescence system and the capability to easily switch between modalities. A laser scanner also provides 3D surface topography for single-view diffuse tomographic reconstructions of internal sources. Background noise is minimized while sensitivity is maximized using a 26 mm square CCD which is cryogenically cooled. An anesthetic system is built-in to keep animals anesthetized for the duration of the experiment. Scans generally take 1-10 minutes to complete with five field of view options ranging from 4 cm to 25 cm. Xenogen applications in oncology offer unique opportunities to measure tumor growth and metastasis in a variety of models. In vivo bioluminescent imaging allows the non-invasive detection and quantification of orthotopic, metastatic and spontaneous tumors in the whole mouse. Xenogen’s biophotonic imaging technology has been optimized for high sensitivity, such that micrometastases can be detected that would otherwise require histopathology to identify. Xenogen oncology models can be used to assess anti-cancer therapies over the course of treatment in vivo. Non-invasive, bioluminescent imaging of tumor growth and metastasis allows longitudinal evaluation of tumor development before, during and after treatment, offering an excellent preclinical strategy to assess tumor response and recurrence. Unlike other non-invasive imaging modalities such as PET or MRI, Xenogen’s imaging technology is rapid, easy to perform and amenable to high throughput. The equipment can be used inside of a barrier facility, and thus can be employed for routine drug screening. Furthermore, the proprietary image analysis software enables accurate quantification for ease of data analysis.
Applications • Quantify tumor burden in the whole mouse
• Detect micrometastases with high sensitivity
• Visualize metastases spontaneously generated from a primary tumor
• Follow responses to therapeutic treatments non-invasively in longitudinal studies